Literature DB >> 9056186

Simultaneous determination of dihydrofluorouracil and 5-fluorouracil in plasma by high-performance liquid chromatography.

S P Ackland1, M B Garg, R H Dunstan.   

Abstract

Dihydrofluorouracil (FUH2) is the product of the first rate-limiting step in catabolism of 5-fluorouracil (5-FU), catalyzed by the enzyme dihydropyrimidine dehydrogenase. In humans, more than 80% of administered 5-FU is degraded through this catabolic pathway. The ability to measure FUH2 and 5-FU simultaneously may provide an index of the extent to which 5-FU is catabolized. A sensitive and efficient extraction and HPLC method has been developed for simultaneous measurement of FUH2 and 5-FU in patients' plasma. Trichloroacetic acid precipitation of plasma proteins was followed by extraction into ethyl acetate, evaporation under nitrogen, and reconstitution in phosphate buffer. The extract was analyzed by isocratic chromatography using a C18 reversed-phase column with uv detection at 268 nm (5-FU) and 220 nm (FUH2). The detection limit is 0.005 nmol on column for aqueous standards or 0.20 microM in 1 ml of plasma standards for both compounds. This method can be applied to pharmacokinetic studies of 5-FU in patients and may be useful as a means of assessing the activity of dihydropyrimidine dehydrogenase.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9056186     DOI: 10.1006/abio.1996.9943

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  6 in total

1.  Pharmacokinetics, a main actor in a many-sided approach to severe 5-FU toxicity prediction.

Authors:  Guido Bocci; Antonello Di Paolo; Cecilia Barbara; Gianluca Masi; Lorenzo Fornaro; Fotios Loupakis; Giacomo Allegrini; Alfredo Falcone; Mario Del Tacca; Romano Danesi
Journal:  Br J Clin Pharmacol       Date:  2008-11-05       Impact factor: 4.335

2.  A phase I trial of daily oral 4'- N -benzoyl-staurosporine in combination with protracted continuous infusion 5-fluorouracil in patients with advanced solid malignancies.

Authors:  Joseph P Eder; Rocio Garcia-Carbonero; Jeffrey W Clark; Jeffrey G Supko; Thomas A Puchalski; David P Ryan; Pamela Deluca; Antoinette Wozniak; Angela Campbell; John Rothermel; Patricia LoRusso
Journal:  Invest New Drugs       Date:  2004-04       Impact factor: 3.850

3.  Predicting 5-fluorouracil toxicity in colorectal cancer patients from peripheral blood cell telomere length: a multivariate analysis.

Authors:  M B Garg; L F Lincz; K Adler; F E Scorgie; S P Ackland; J A Sakoff
Journal:  Br J Cancer       Date:  2012-09-18       Impact factor: 7.640

Review 4.  A Critical Review on Clinical Application of Separation Techniques for Selective Recognition of Uracil and 5-Fluorouracil.

Authors:  Khushaboo Pandey; Rama Shankar Dubey; Bhim Bali Prasad
Journal:  Indian J Clin Biochem       Date:  2015-02-15

5.  Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene.

Authors:  J G Maring; A B P van Kuilenburg; J Haasjes; H Piersma; H J M Groen; D R A Uges; A H Van Gennip; E G E De Vries
Journal:  Br J Cancer       Date:  2002-04-08       Impact factor: 7.640

Review 6.  Ethnic Diversity of DPD Activity and the DPYD Gene: Review of the Literature.

Authors:  Cassandra White; Rodney J Scott; Christine Paul; Andrew Ziolkowski; David Mossman; Stephen Ackland
Journal:  Pharmgenomics Pers Med       Date:  2021-12-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.